The adjusted group result fell, however, by four percent to almost 1.8 billion euros.
“Corona will still present us with some challenges in the current year,” said Fresenius boss Stephan Sturm. “It is all the more important to increase our efficiency and thus improve our cost base.” Fresenius wants to expand growth areas such as digital medical offers, home dialysis for kidney patients, business with fertility clinics and copycat drugs for biotech drugs.
Last year, Germany’s largest private hospital operator with 89 hospitals felt the pandemic. Operations had to be postponed to keep intensive care beds free for corona patients. Since the pandemic was relatively mild, many beds were empty. State aid for hospitals could only reduce the failures.
Hope for the second half of the year
The group warned that the conditions in key markets would only improve in the second half of the year, pointing to high risks. “However, this is heavily dependent on the rapidly advancing vaccination coverage of the population in these markets.” This year, Fresenius is now expecting a currency-adjusted increase in sales in the low to mid-single-digit percentage range.
The management confirmed the targets for the adjusted group result, it should remain “at least roughly stable”.
On the stock exchange, the Fresenius and FMC prices changed little on Tuesday morning in a weak market environment. At the beginning of February, FMC had caused a further slide in prices for both securities with a gloomy outlook.
The FMC papers, which are also listed in the Dax, have fallen by more than a third since the end of 2017.